Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer-Reference-Cited by-同舟云学术

Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer

Published:2020-07-22 Issue:2 Volume:16 Page:65-73
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Musaelyan A. A.¹^ORCID,Nazarov V. D.¹^ORCID,Lapin S. V.¹^ORCID,Boriskin A. G.¹,Reva S. A.¹^ORCID,Lebedev D. G.²,Yakovlev V. D.¹,Viktorov D. A.³,Toropovskiy A. N.³,Emanuel V. L.¹^ORCID,Al-Shukri S. Kh.¹^ORCID,Petrov S. B.¹

Affiliation:

1. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

2. Alexander Hospital; 4 Prospekt Solidarnosti

3. TestGen

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference23 articles.

1. Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018. DOI: 10.3322/caac.21492.

2. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618—29. DOI: 10.1016/j.eururo.2016.08.003.

3. Leyten G.H., Hessels D., Jannink S.A. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65(3):534—42. DOI: 10.1016/j.eururo.2012.11.014.

4. Hendriks R.J., Van Oort I.M., Schalken J.A. Blood-based and urinary prostate cancer biomarkers: A review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20(1):12—9. DOI: 10.1038/pcan.2016.59.

5. Scattoni V., Lazzeri M., Lughezzani G. et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013;190(2):496—501. DOI: 10.1016/j.juro.2013.02.3184.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen;Research and Practical Medicine Journal;2023-03-25

2. Characteristics of the phagocytic component of the immune system in early-stage gastric cancer;Onkologiya. Zhurnal imeni P.A.Gertsena;2023

3. The effectiveness of laboratory and radiological diagnosis of localized and locally advanced prostate cancer;Onkologiya. Zhurnal imeni P.A.Gertsena;2022